Cytokeratin 19 (CK19) As A Marker For Epithelial Differentiation And Malignant Transformation: Its Clinical Relevance In Diagnosis, Prognosis And Treatment Response Monitoring

References

[1] Moll R, Franke WW, Schiller DL, et al. (1982). The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell, 31(1): 11- 24.

[2] Hofmeier J. Horn-lime plastic masses from keratin substances. Ger pat no 184915; 1905.

[3] Steinert PM, Idler WW, Zimmerman SB. (1976). Self-assembly of bovine epidermal α- keratin. J Mol Biol.; 108: 547–567.

[4] Bader BL, Magin TM, Hatzfeld M, Franke WW. (1986). Amino acid sequence and gene organization of cytokeratin no. 19, an exceptional tail-less intermediate filament protein. The EMBO Journal; 5(8), 1865– 1875.

[5] Fradette J, Germain L, Seshaiah P, Coulombe PA. (1998). The type I keratin 19 possesses distinct and context-dependent assembly properties. J Biol Chem.; 273 (52): 35176-84.

[6] Stasiak PC, Purkis PE, Leigh IM et al. (1989). Keratin 19: predicted amino acid sequence and broad tissue distribution suggest it evolved from keratinocyte keratins. J Invest Dermatol.; 92: 707–16. TABLE III - SUMMARY OF STUDIES OF CK19 AS A TREATMENT MONITORING MARKER Type of Cancer Study Notable Outcomes Reference Non-small cell lung cancer (NSCLC) RT-PCR Positive CK19 mRNA expression in PB after definitive chemo-radiation was an unfavorable prognostic predictor Chen et al.

[7] Head and neck cancer (HNC) ELISA CYFRA 21-1 levels dropped significantly 24 hours after successful operation. Kwarciak et al.

[8] Endometrial cancer (EC) OSNA OSNA represent an efficient intra-operative tool for early-stage EC detection Fanfani et al.

[9] Lung cancer ELISA Serial monitoring of CYFRA 21-1 could be a useful prognostic tool of treatment response and longer survival Hamzaoui et al.

[10] RT-PCR CTCs could be valuable for evaluating the efficacy of radiotherapy and deciding on systemic therapy. Ge et al.

[11] OSNA CK19 mRNA was the best biomarker for lymph node metastases detection in NSCLC Inoue et al.

[12] Breast cancer Flow cytometry (blood) Though not sensitive as RT-PCR but offered the possibility to monitor disease progression and the risk of relapse Wang et al.

[13] ELISA Elevated preoperative levels of serum CYFRA 21-1 decreased to normal levels after curative operation Nakata et al.

[14] OSNA OSNA is a reliable tool for intraoperative diagnosis of whole SLNs during surgery of breast cancer. Chaudhry et al.

[15] Human hepatocellular carcinoma (HCC) ELISA CYFRA 21- 1 levels were regulated by CK19 function and reflected the treatment efficacy in CK19-positive HCC-CSCs. Kawai et al.

[16] IHC (lymph nodes) CK19 expression in regional LN of HCC was associated with LNM and an extremely poor outcome after operation Lee et al.

[17] Colon cancer OSNA OSNA had high sensitivity and specificity in detecting small lymph node tumor infiltrates Güller et al.

[18] Hesse M, Franz T, Tamai Y, et al. (2000). Targeted deletion of keratins 18 and 19 leads to trophoblast fragility and early embryonic lethality. The EMBO Journal; 19 (19): 5060- 5070.

[19] Bartek J, Bartkova J, Taylor-Papadimitriou J, et al. (1986). Differential expression of keratin 19 in normal human epithelial tissues revealed by monospecific monoclonal antibodies. Histochem J.; 18: 565-575.

[20] Michel M, Török NJ, Godbout MJ, Germain L. (1996). Keratin 19 as a biochemical marker of skin stem cells in vivo and in vitro: Keratin 19 expressing cells are differentially localized in function of anatomic sites, and their number varies with donor age and culture stage. Journal of Cell Science; 109 (Pt 5) (5): 1017-28.

[21] Quaroni A, Calnek D, Quaroni E, Chandler JS. (1991). Keratin Expression in Rat Intestinal Crypt and Villus Cells - Analysis with a Panel of Monoclonal-Antibodies. Journal of Biological Chemistry; 266(18): 11923-11931.

[22] Blyszczuk P, Asbrand C, Rozzo A, et al. (2004). Embryonic Stem Cells Differentiate into Insulin-Producing Cells Without Selection of Nestin-Expressing Cells. Int J Dev Biol.; 48: 1095-1104

[23] Fridmacher V, Le Bert M, Guillou F, Magre S. (1995). Switch in the expression of the K19/K18 keratin genes as a very early evidence of testicular differentiation in the rat. Mech Dev.; 52 (2-3): 199-207.

[24] Speight PM, Khurram SA, Kujan O. (2018). Oral potentially malignant disorders: risk of progression to malignancy. Oral Surg Oral Med Oral Pathol Oral Radiol.; 125 (6): 612- 627.

[25] Fillies T, Jogschies M, Kleinheinz J, et al. (2007). Cytokeratin alteration in oral leukoplakia and oral squamous cell carcinoma. Oncol Rep.; 18 (3): 639-43.

[26] Coltrera M, Zarbo RJ, Sakr WA, Gown AM. (1992). Markers for dysplasia of the upper aerodigestive tract. Suprabasal expression of PCNA, p53, and CK19 in alcohol-fixed, embedded tissue. Am J Pathol.; 141:817-25.

[27] Mohanta A, Mohanty PK, Parida G. (2014). Pattern of Keratinization in Oral Squamous Cells during Carcinogenesis. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS); 13 (7) IV: 83-91.

[28] Malik SN, Vyas Z, Kotari H, et al. (2018). Association of Clinical Stages of Oral Submucous Fibrosis to Cytokeratin 19 Immunohistochemical Staining. World J Dent.; 9 (2): 117-121.

[29] Jacques CMC, Pereira AJC, Maia V, et al. (2009). Expression of cytokeratins 10, 13, 14 and 19 in oral lichen planus. Journal of Oral Science; 51 (3): 355-365.

[30] Wallenius K, Lekholm U. (1973). Oral cancer in rats induced by the water-soluble carcinogen 4-nitrochinoline N-oxide. Odontol Revy.; 24(1): 39-48.

[31] Yan F, Kang X, Li C, Minhai N. (2013). Expression of cytokeratin 19 and connexin 43 in 4-nitroquinoline-l-oxide-induced rat tongue carcinogenesis. Hua Xi Kou Qiang Yi Xue Za Zhi; 31: 237-41.

[32] Kowalik MA, Sulas P, Ledda-Columbano GM, et al. (2015). Cytokeratin-19 positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis. Oncotarget; 6 (36): 38749–38763.

[33] Lee H, Lee H, Cho YK. (2017). CK7 and CK19 expression in high grade cervical intraepithelial neoplasm and squamous cell carcinoma and their possible association in cervical carcinogenesis. Diagnostic Pathology; 12:18.

[34] Martin TA, Ye L, Sanders AJ, et al. (2003). Cancer Invasion and Metastasis: Molecular and Cellular Perspective. In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000 -2013. https://www.ncbi.nlm.nih.gov/books/NBK16 4700/.

[35] Bambang IF, Lu D, Li H, Chiu LL, Lau QC, Koay E, Zhang D. (2009). Cytokeratin 19 regulates endoplasmic reticulum stress and inhibits ERp29 expression via p38 MAPK/XBP-1 signaling in breast cancer cells. Exp Cell Res.; 315(11): 1964-74.

[36] Saha SK, Kim K, Yang GM, et al. (2018). Cytokeratin 19 (KRT19) has a role in the reprogramming of cancer stem cell-like cells to less aggressive and more drug-sensitive cells. Int J Mol Sci.; 19: 1423.

[37] Dencic TI, Cvejic D, Paunovic I, et al. (2013). Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior. Med Oncol.; 30: 362.

[38] Giovanella L, Treglia G, Verburg FA, et al. (2012). Serum cytokeratin 19 fragments: a dedifferentiation marker in advanced thyroid cancer. European Journal of Endocrinology; 167: 793–797.

[39] Govaere O, Petz M, Wouters J, et al. (2017). The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma. Oncogene; 36: 6605–6616.

[40] Bjorklund B, Bjorklund V. (1957). Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique; presence of an insoluble, heat- labile tumor antigen. Int Arch Allergy Appl Immunol.; 10:153-84.

[41] Coons AH, Creech HJ, Jones RN. (1942). Immunological properties of an antibody containing a fluorescent group. Proc Soc Exp Biol Med.; 47: 200-202.

[42] Traweek ST, Liu J, Battifora H. (1993). Keratin gene expression in non-epithelial tissues: detection with polymerase chain reaction. American Journal of Pathology; 4:1111–1117.

[43] Stewart CJ, Crook ML, Lacey J, Louwen K. (2011). Cytokeratin 19 expression in normal endometrium and in low-grade endometrioid adenocarcinoma of the endometrium. Int J Gynecol Pathol.; 30 (5): 484-91.

[44] Bremmer F, Ströbel P, Jarry H, et al. (2015). CK19 is a sensitive marker for yolk sac tumours of the testis. Diagnostic Pathology; 10: 7.

[45] Heyl J and Mehregan D. (2008). Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas. J Cutan Pathol.; 35: 40–45.

[46] Khurana KK, Truong LD, LiVolsi VA, Baloch ZW. (2003). Cytokeratin 19 Immunolocalization in Cell Block Preparation of Thyroid Aspirates an Adjunct to Fine-Needle Aspiration Diagnosis of Papillary Thyroid Carcinoma. Arch Pathol Lab Med.: 127.

[47] Naseem N, Reyaz N, Nagi AH, et al. (2010). Immunohistochemical Expression of Cytokeratin-19 in Non-Small Cell Lung Carcinomas - An Experience from a Tertiary Care Hospital in Lahore. International Journal of Pathology; 8 (2): 54-59.

[48] Zhang Y, He J. (2013). The development of targeted therapy in small cell lung cancer. Journal of Thoracic Disease; 5(4): 538–548.

[49] Yu XF, Yang HJ, Lei L, et al. (2016). CK19 mRNA in blood can predict non-sentinel lymph node metastasis in breast cancer. Oncotarget; 7 (21): 30504-30510.

[50] Suo J, Wang Q, Jin HJ, Li H, Zhao H. (2006). K-19 mRNA RT -PCR in detecting micrometastasis in regional lymph nodes of gastric cancer. World Journal of Gastroenterology: WJG.; 12 (32): 5219- 5222.

[51] Zapata M, Cohen C, Siddiqui MT. (2007). Immunohistochemical expression of SMAD4, CK19, and CA19-9 in fine needle aspiration samples of pancrea tic adenocarcinoma: Utility and potential role. CytoJournal; 4: 13.

[52] Tao L, Lefèvre M, Ricci S, et al. (2006). Detection of occult carcinomatous diffusion in lymph nodes from head and neck squamous cell carcinoma using real-time RT–PCR detection of cytokeratin 19 mRNA. British Journal of Cancer; 94 (8): 1164-1169.

[53] Kamiya M, Ichiki Y, Kamiya H, Yamamoto A, Kitajima Y. (2003). Detection of non- melonama skin cancer micrometastases in lymph nodes by using reverse transcriptase- polymerase chain reaction for keratin 19 mRNA. Br J Dermatol.; 149(5): 998-1005.

[54] Stieber P, Hasholzner U, Bodenmuller H, et al. (1993). CYFRA 21-1. A new marker in lung cancer. Cancer; 72(3): 707–713.

[55] Xu D, Li X, Zheng S, Jiang W. (2006). Quantitative real-time RT-PCR detection for CEA, CK20 and CK19 mRNA in peripheral blood of colorectal cancer patients. Journal of Zhejiang University Science; 7 (6): 445-451.

[56] Brotherick I, Robson CN, Browell DA. et al. (1998). Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression. Cytometry; 32(4): 301-8.

[57] Ebieda SA, Abdel-Rehimb WMA, El- Benhawyc SA, et al. (2017). Serum CYFRA 21-1 in Egyptian women with breast cancer. Alexandria Journal of Medicine; 53 (1): 41- 47

[58] Qiao YF, Chen CG, Yue J, Ma MQ, Ma Z, Yu ZT. (2017). Prognostic significance of preoperative and postoperative CK19 and CEA mRNA levels in peripheral blood of patients with gastric cardia cancer. World Journal of Gastroenterology; 23(8): 1424- 1433.

[59] Zhong LP, Chen WT, Zhang CP, Zhang ZY. (2007). Increased CK19 expression correlated with pathologic differentiation grade and prognosis in oral squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.; 104(3): 377-84.

[60] Schmitt AM, Anlauf M, Rousson V, et al. (2007). WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol.; 31 (11): 1677-82.

[61] Ernst J, Ikenberg K, Apel B, et al. (2016). Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue. Oncotarget; 7 (46): 76151-76158.

[62] Du YY, Zhang QJ, Sun GP. (2016). Expression and Clinical Significance of Cytokeratin-19 and Thymidine Kinase-1 in Advanced Gastrointestinal Cancer. Chinese Medical Journal; 129 (18): 2168-2172

[63] Van Sprundel RG, van den Ingh TS, Desmet VJ, et al. (2010). Keratin 19 marks poor differentiation and a more aggressive behaviour in canine and human hepatocellular tumours. Comparative Hepatology; 9: 4.

[64] Kiruthiga KG, Ramakrishna B, Saha S, Sen S. (2018). Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival. Journal of Gastrointestinal Oncology; 9 (2): 326-337.

[65] Winter SC, Stephenson SA, Subramaniam SK, et al. (2009). Long-term survival following the detection of circulating tumour cells in head and neck squamous cell carcinoma. BMC Cancer; 9: 424.

[66] Liu M, Mor G, Cheng H. et al. (2013). High frequency of putative ovarian cancer stem cells with CD44/CK19 co-expression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. Reproductive Sciences; 20(5): 605-615.

[67] Notomi T, Okayama H, Masubuchi H. et al. (2000). Loop-mediated isothermal amplification of DNA. Nucleic Acids Res.; 28(12): E63.

[68] Chen TF, Jiang GL, Fu XL, et al. (2007). CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor. Lung Cancer; 56 (1): 105- 14.

[69] Kwarciak JM, Rutkowski T, Składowski K, et al. (2015). CYFRA 21-1 as a prognostic marker of tumor response to radiation alone or combined with chemotherapy in patients with carcinoma of larynx or hypopharynx. International Journal of New Technology and Research (IJNTR).; 1 (7): 30-36.

[70] Fanfani F, Monterossi G, Ghizzoni V, et al. (2018). One-Step Nucleic Acid Amplification (OSNA): A fast molecular test based on CK19 mRNA concentration for assessment of lymph-nodes metastases in early stage endometrial cancer. Troncone G, ed. PLoS ONE.; 13 (4): e0195877.

[71] Hamzaoui A, Thomas P, Castelnau O. et al. (1997). Usefulness of longitudinal evaluation of Cyfra 21-1 variations in advanced lung cancer monitoring. Lung Cancer; 0169-5002, 16(2): 191-202,

[72] Ge M, Shi D, Wu Q, Wang M, Li L. (2005). Fluctuation of circulating tumor cells in patients with lung cancer. J Cancer Res Ther.; 1(4).

[73] Inoue M, Hiyama K, Nakabayashi K. et al. (2012). An accurate and rapid detection of lymph node metastasis in non-small cell lung cancer patients based on one-step nucleic acid amplification assay. Lung Cancer; 78: 212– 218

[74] Wang L, Wang Y, Liu Y, Cheng M, Wu X, Wei H. (2009). Flow cytometric analysis of CK19 expression in the peripheral blood of breast carcinoma patients: relevance for circulating tumor cell detection. Journal of Experimental & Clinical Cancer Research; 28: 57.

[75] Nakata B, Takashima T, Ogawa Y, et al. (2004). Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumor marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br. J. Cancer.; 31 (91): 873–8.

[76] Chaudhry A, Williams S, Cook J. (2014). The real-time intra-operative evaluation of sentinel lymph nodes in breast cancer patients using one step nucleic acid amplification (OSNA) and implications for clinical decision-making. Eur J Surg Oncol.; 40: 150- 7.

[77] Kawai T, Yasuchika K, Ishii T. et al. (2017). Identification of keratin 19‐positive cancer stem cells associating human hepatocellular carcinoma using CYFRA 21‐1. Cancer Medicine; 6(11): 2531-2540.

[78] Lee CW, Kuo WL, Yu MC, et al. (2013). The expression of cytokeratin 19 in lymph nodes was a poor prognostic factor for hepatocellular carcinoma after hepatic resection. World Journal of Surgical Oncology; 11: 136.

[79] Güller U, Zettl A, Worni M, et al. (2012). Molecular Investigation of Lymph Nodes in Colon Cancer Patients Using One-Step Nucleic Acid Amplification (OSNA): A New Road to Better Staging? Cancer; 118 (24): 6039-6045.

@article{1700752,
      author = {Bonaventure Mujyambere, S. Suja, Rama Jayaraj },
      title = {Cytokeratin 19 (CK19) As A Marker For Epithelial Differentiation And Malignant Transformation:  Its Clinical Relevance In Diagnosis, Prognosis And Treatment Response Monitoring},
      journal = {Iconic Research And Engineering Journals},
      year = {2018},
      volume = {2},
      number = {3},
      pages = {51-61},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1700752.pdf},
      abstract = {Cytokeratin 19 (CK19) is a type I cytokeratin found mostly in epithelial tissues with high plasticity such as stem cells, transforming cells or tumorous cells. CK19 increases its expression level during epithelial embryogenesis, tissues regeneration, tissue repair as well as tissue development and has shown to have an increasing expression in carcinogenesis of CK19-positive cancers from normal tissues to premalignant lesions to carcinoma in situ. The insertion of CK19 in CK19-negative carcinoma cells induced the metastatic progression characterized by angiogenesis, invasion to surrounding tissues, increased proliferation and drug resistance. Hence, the detection of intracellular CK19 protein by immunohistochemistry (IHC), CK19 transcripts by quantitative Real time RT-PCR or One-step nucleic acid amplification (OSNA) and serum CK19 fragments such as Cyfra 21-1 by enzyme-linked immunosorbent assay (ELISA) could help in diagnosis to confirm the presence of the cancerous cells, in prognosis to predict the course the cancer is mostly likely to take and in treatment response monitoring to investigate the effectiveness of the treatment so that the early adjuvant therapy could be used in case the treatment was found ineffective during the follow-up studies.},
      keywords = {Cytokeratin 19, epithelial differentiation, malignant transformation, diagnosis, prognosis, treatment response.},
      month = {September},
  }